Alexei Tumanov | Immunology | Innovative Research Award

Published on by Molecular Biologist

Innovative Research Award

Alexei Tumanov
The University of Texas at San Antonio, United States

Alexei Tumanov
Affiliation The University of Texas at San Antonio
Country United States
Google Scholar ID EDMA9agAAAAJ
Documents 97
Citations 7,514
h-index 41
Subject Area Immunology
Event International Molecular Biologist Awards
ORCID 0000-0001-6042-0152
Scopus 35351917100

Alexei Tumanov is an immunology researcher affiliated with the University of Texas at San Antonio and the Department of Microbiology, Immunology and Molecular Genetics at UT Health San Antonio. Institutional and bibliographic sources describe his research in relation to cytokine signaling, lymphotoxin biology, immune regulation, lymphoid-organ biology, inflammation, cancer immunotherapy and neuroimmune mechanisms.[1][2]

Abstract

Alexei Tumanov’s research profile is centered on molecular and cellular immunology, with particular emphasis on lymphotoxin signaling and its relationship to immune-system organization, inflammatory responses and disease mechanisms. His institutional research record includes investigations of lymphotoxin-beta receptor signaling, innate and adaptive immune responses, cancer immunotherapy and neuroimmune interactions.[1] Recent publications have examined lymphotoxin-beta receptor regulation of chronic pain, ferroptosis-associated regulation of innate lymphoid cell responses, and strategies intended to separate antitumor activity from immune-mediated toxicity in CD137-directed cancer immunotherapy.[2][3]

Keywords

  • Immunology
  • Molecular Immunology
  • Lymphotoxin Signaling
  • Lymphotoxin-beta Receptor
  • Cytokine Biology
  • Innate Immunity
  • Cancer Immunotherapy
  • Neuroimmune Regulation
  • Inflammation

Introduction

Molecular immunology examines how signaling pathways, immune-cell interactions and tissue environments regulate protective immunity and inflammatory disease. Within this field, lymphotoxin signaling represents an important area for studying the organization and maintenance of lymphoid tissues and the communication between immune and non-immune cells. Tumanov’s research has addressed these mechanisms through experimental studies of lymphotoxin pathways and their roles in immune-system development and disease-related processes.[1]

His earlier work included conditional targeting studies of lymphotoxin pathways in lymphoid organs. Such research contributed to the characterization of cell-specific functions of lymphotoxin and lymphotoxin-beta receptor signaling in peripheral lymphoid-organ development and maintenance.[4] More recent work has extended this research framework to inflammatory bowel disease, cancer immunotherapy and neuroimmune signaling.[2][3]

Research Profile

Institutional information identifies Tumanov as a researcher in the Department of Microbiology, Immunology and Molecular Genetics at UT Health San Antonio. His documented research interests include immune regulation, cytokine signaling and lymphotoxin biology. His research profile also encompasses interactions between immune pathways and pathological processes, including inflammation, cancer and chronic pain.[1][2]

The research program has included both fundamental and disease-oriented investigations. Earlier studies examined lymphotoxin-dependent organization of lymphoid organs, while later studies have investigated how related signaling mechanisms can influence therapeutic toxicity, inflammatory responses and sensory-neural processes.[4][5]

Research Contributions

A central contribution of Tumanov’s research is the investigation of lymphotoxin-beta receptor signaling as a regulator of immune and tissue processes. Experimental work has examined how this receptor pathway contributes to lymphoid-organ development and maintenance and how alterations in the pathway can affect inflammatory and pathological responses.[4]

In cancer immunotherapy, Tumanov has investigated mechanisms associated with the toxicity of CD137-directed treatment. A Cancer Prevention and Research Institute of Texas grant lists him as principal investigator for a project examining the role of lymphotoxin-beta receptor signaling in overcoming liver toxicity associated with anti-CD137 cancer immunotherapy.[5]

His recent collaborative research has also examined neuroimmune mechanisms. A 2026 Cell Reports publication reported that lymphotoxin-beta receptor signaling is involved in the development of chronic pain, providing experimental evidence connecting an immune signaling pathway with sensory processes.[3]

Additional work published in Cellular & Molecular Immunology examined ferroptosis in relation to ILC2 responses in inflammatory bowel disease. The article identifies lymphotoxin-related immunological research within a broader investigation of inflammatory mechanisms affecting innate lymphoid cells.[2]

Publications

Tumanov’s publication record spans molecular immunology, cytokine signaling, lymphoid-organ biology, inflammatory disease, cancer immunotherapy and neuroimmune regulation. His institutional profile lists publications including recent studies in Science Advances, Cell Reports and Cellular & Molecular Immunology.[1]

  • Tumanov, A. V., et al. (2026). Lymphotoxin-beta receptor controls the development of chronic pain. Cell Reports, 45(4), 117269. DOI: 10.1016/j.celrep.2026.117269.[3]
  • Korchagina, A. A., & Tumanov, A. V. (2026). Ferroptosis shapes ILC2 responses in inflammatory bowel disease. Cellular & Molecular Immunology, 23, 583–585. DOI: 10.1038/s41423-026-01404-z.[2]
  • Shein, S. A., Korchagina, A. A., Wang, L.-J., et al., including Tumanov, A. V. (2026). Selective elimination of circulating effector CD8 T cells via LTβR blockade separates anti-CD137 efficacy from toxicity. Science Advances, 12(17), eaea8737.[1]
  • Tumanov, A. V., et al. (2003). Dissecting the role of lymphotoxin in lymphoid organs by conditional targeting. Immunological Reviews. DOI: 10.1034/j.1600-065X.2003.00071.x.[4]

Research Impact

The documented research program connects fundamental immunological mechanisms with disease-oriented questions. Institutional records describe grant-supported research into the regulation of cancer immunotherapy toxicity and the role of lymphotoxin-beta receptor signaling in sensory neurons, while recent publications extend the research into chronic pain and inflammatory bowel disease.[2][3][5]

The quantitative metrics supplied for this recognition profile list 97 documents, 7,514 citations and an h-index of 41. Such metrics are bibliographic indicators and should be interpreted according to the database, date of retrieval and author-profile methodology used. The supplied Google Scholar, ORCID and Scopus identifiers provide external routes for verification and updating of these records.

The translational relevance of the research is also reflected in grant-supported projects. CPRIT records identify Tumanov as principal investigator of research concerning anti-CD137 cancer immunotherapy and lymphotoxin-beta receptor signaling, illustrating an application-oriented dimension of his immunological research.[5]

Award Suitability

The documented research themes are closely associated with molecular and cellular immunology, including cytokine signaling, lymphotoxin biology, immune-cell regulation and disease mechanisms. His publication record and institutionally documented research projects provide identifiable evidence of sustained activity in these areas.[1][5]

For the purposes of the International Molecular Biologist Awards, the supplied recognition category is the Innovative Research Award. This article records the relationship between the stated award category and the documented research profile without assigning an independent assessment of scientific merit.

Conclusion

Alexei Tumanov’s research profile encompasses molecular immunology, lymphotoxin signaling and the regulation of immune responses in physiological and pathological settings. His documented work includes studies of lymphoid-organ biology, inflammatory disease, cancer immunotherapy and neuroimmune mechanisms. Recent publications demonstrate continuing investigation of lymphotoxin-beta receptor pathways and immune-cell regulation, while grant records document support for translational research involving cancer immunotherapy.[1][2][3][5]

References

  1. UT Health San Antonio. (n.d.). Tumanov, Alexei, M.D., Ph.D. — Microbiology, Immunology & Molecular Genetics. Institutional researcher profile.
    https://lsom.uthscsa.edu/mimg/team-member/alexei-v-tumanov-m-d-ph-d/
  2. Korchagina, A. A., & Tumanov, A. V. (2026). Ferroptosis shapes ILC2 responses in inflammatory bowel disease. Cellular & Molecular Immunology, 23, 583–585. DOI: 10.1038/s41423-026-01404-z.
    https://doi.org/10.1038/s41423-026-01404-z
  3. Tumanov, A. V., Mecklenburg, J. M., Belugin, S., et al. (2026). Lymphotoxin-beta receptor controls the development of chronic pain. Cell Reports, 45(4), 117269. DOI: 10.1016/j.celrep.2026.117269.
    https://doi.org/10.1016/j.celrep.2026.117269
  4. Tumanov, A. V., et al. (2003). Dissecting the role of lymphotoxin in lymphoid organs by conditional targeting. Immunological Reviews. DOI: 10.1034/j.1600-065X.2003.00071.x.
    https://doi.org/10.1034/j.1600-065X.2003.00071.x
  5. Cancer Prevention and Research Institute of Texas. (2022). Grant RP220470: Overcoming liver toxicity of anti-CD137 cancer immunotherapy. Principal Investigator: Alexei Tumanov. University of Texas Health Science Center at San Antonio.
    https://www.cprit.texas.gov/grants-funded/grants/rp220470

georges Bahr | Immunology | Innovative Research Award

Published on by Molecular Biologist

 

Innovative Research Award

              Georges Bahr
Researcher Georges Bahr
Affiliation University of Balamand
Country Lebanon
Scopus ID 7102520346
Documents 116
Citations 2,560
h-index 28
Subject Area Immunology
Event International Molecular Biologist Awards

Georges Bahr

University of Balamand, Lebanon

Georges Bahr is affiliated with the University of Balamand in Lebanon and has an indexed research profile in the field of immunology. The Innovative Research Award recognizes researchers whose scholarly work demonstrates sustained scientific activity, originality, and measurable contribution to their respective fields. According to the supplied Scopus profile information, the researcher has 116 documents, 2,560 citations, and an h-index of 28.[1]

Abstract

Georges Bahr’s academic profile reflects an established research record in immunology, supported by a substantial body of indexed scholarly publications and measurable citation activity. The supplied bibliometric data identify 116 documents, 2,560 citations, and an h-index of 28. These indicators provide quantitative evidence of research visibility and scholarly influence, while qualitative assessment of individual publications remains important when evaluating scientific innovation and significance.[1][2]

Keywords

Immunology, Molecular Biology, Cellular Immunology, Immune Response, Biomedical Research, Scientific Publications, Research Impact, Citation Analysis, Translational Research, Academic Excellence.

Introduction

Immunology is a multidisciplinary area of biomedical science concerned with the study of immune-system components, immune responses, host–pathogen interactions, inflammation, and mechanisms underlying immune-mediated disease. Contemporary immunological research frequently integrates molecular biology, cellular biology, genetics, microbiology, and clinical science to investigate mechanisms operating at multiple biological scales.[3]

Academic research profiles in immunology may be assessed using both qualitative and quantitative measures. Bibliometric indicators, including publication counts, citation counts, and the h-index, can provide useful contextual information regarding scholarly dissemination and influence, although they do not independently establish the scientific quality of individual studies.[2][4]

Research Profile

Georges Bahr is associated with the University of Balamand, Lebanon, and is represented in Scopus under author identifier 7102520346. The supplied profile records 116 documents and 2,560 citations, with an h-index of 28. These figures indicate a sustained publication record and citation presence within the indexed scholarly literature.[1]

  • Institutional affiliation: University of Balamand.
  • Country: Lebanon.
  • Primary subject area: Immunology.
  • Scopus author identifier: 7102520346.
  • Indexed documents: 116.
  • Reported citations: 2,560.
  • Reported h-index: 28.

Research Contributions

Research in immunology contributes to understanding the molecular and cellular mechanisms responsible for immune recognition, regulation, inflammation, host defense, and immune-associated disorders. Within this broad discipline, scholarly contributions can encompass experimental investigation, molecular characterization, cellular studies, disease mechanisms, and translational approaches. The available profile information establishes Georges Bahr’s disciplinary classification but does not provide sufficient evidence to assign specific individual discoveries or mechanisms without reviewing the underlying publications.[1][3]

The combination of publication activity and citation accumulation provides an indication that the researcher’s work has been disseminated within the scholarly literature. Detailed evaluation of originality, methodological rigor, reproducibility, and practical significance should be conducted at the publication level by subject-matter experts.[4]

Publications

The supplied Scopus information records 116 documents associated with Georges Bahr. Scopus provides bibliographic and citation information that can be used to examine publication output, citation patterns, collaboration, and subject-area distribution. Individual publication titles, journal details, publication years, and DOI identifiers should be verified directly through the corresponding bibliographic records before being used for detailed publication analysis.[1]

  • Total documents reported in the supplied Scopus profile: 116.
  • Research classification: Immunology.
  • Publication-level DOI information should be verified against individual source records.

Research Impact

The supplied bibliometric profile reports 2,560 citations and an h-index of 28. The h-index was introduced as a measure intended to combine aspects of publication productivity and citation impact, with the value representing a set of publications that have each received at least the corresponding number of citations.[4]

Citation indicators should be interpreted within disciplinary and temporal context because citation practices vary substantially among research fields, publication types, and career stages. Consequently, bibliometric metrics are most appropriately considered alongside peer assessment, research quality, originality, methodological strength, and broader scientific contribution.[2][5]

Award Suitability

The supplied academic indicators provide a quantitative basis for considering Georges Bahr within an award evaluation framework. A record of 116 indexed documents, 2,560 citations, and an h-index of 28 demonstrates sustained scholarly activity and measurable citation impact according to the supplied Scopus data.[1]

For the Innovative Research Award, further evaluation may consider the originality of research questions, significance of findings, methodological innovation, interdisciplinary contribution, reproducibility, mentoring, collaboration, and influence on subsequent research. Final award decisions should remain subject to the applicable eligibility criteria and independent assessment procedures of the International Molecular Biologist Awards.

Conclusion

Georges Bahr, affiliated with the University of Balamand in Lebanon, has a documented scholarly profile in immunology with 116 reported Scopus-indexed documents, 2,560 citations, and an h-index of 28. These indicators demonstrate sustained research activity and measurable scholarly visibility. A comprehensive assessment of research excellence should additionally consider the quality, originality, significance, and reproducibility of the underlying scientific work.[1][2]

References

  1. Elsevier. (n.d.). Scopus author details: Georges Bahr, Author ID 7102520346. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=7102520346
  2. Elsevier. (n.d.). Scopus: Abstract and citation database for peer-reviewed literature. Scopus.
    https://www.scopus.com/
  3. Murphy, K., & Weaver, C. (2016). Janeway’s Immunobiology (9th ed.). Garland Science.
    https://doi.org/10.1201/9781315533247
  4. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output. Proceedings of the National Academy of Sciences, 102(46), 16569–16572.
    https://doi.org/10.1073/pnas.0507655102
  5. International Molecular Biologist Awards. (n.d.). Official Award Website.
    https://molecularbiologist.org/

Manuela Cappelletti | Immunology | Industry Impact Award

Published on by Molecular Biologist

Mrs. Manuela Cappelletti | Immunology | Industry Impact Award 

Senior lab biologist | TAKIS srl | Italy

Mrs. Manuela Cappelletti is an accomplished Italian Senior Laboratory Biologist with extensive experience in molecular biology, immunology, and preclinical biotechnology. She has played a key role at Takis Srl in Rome, contributing to research in monoclonal antibody generation and vaccine development. Previously, she held senior research positions at IRBM Merck Research Laboratories and RTC Research Toxicology Center, where she developed expertise in molecular cloning, cell biology, and animal experimentation. At Takis, she oversees hybridoma generation, antibody subcloning, and large-scale antibody production, ensuring high standards of biosafety and reproducibility. Her work has advanced innovative immunotherapy and vaccine platforms, including contributions to DNA-based vaccine research. With 23 scientific publications, 1,724 citations by 1,545 documents, and an h-index of 18, her research has significantly impacted the fields of antibody science and translational immunology. Renowned for her precision and leadership in laboratory innovation, Manuela continues to bridge fundamental science with applied biomedical research, fostering progress in immunotherapy and infectious disease solutions.

Profile: Scopus | ORCID

Featured Publications

Cappelletti, M., et al. (n.d.). Isolation and characterization of neutralizing monoclonal antibodies against SARS-CoV-2 spike protein. Antibodies (Basel). Cited by 12.

Cappelletti, M., et al. (n.d.). COVID-eVax: An electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD. Molecular Therapy, 30(4). Cited by 58.

Cappelletti, M., et al. (n.d.). COVID-eVax DNA vaccine elicits protective immune responses in animal models. bioRxiv. Cited by 72.

Cappelletti, M., et al. (n.d.). Gene electro-transfer improves transduction by modifying the fate of intramuscular DNA. Journal of Gene Medicine, 5(3). Cited by 130.

Cappelletti, M., et al. (n.d.). C/EBP beta and acute phase gene regulation in liver cells. Cell Death and Differentiation, 3(2). Cited by 45.

 

MYTHILEESWARI LAKSHMIKANTHAN | immunology | Women Researcher Award

Published on by Molecular Biologist

Mrs. MYTHILEESWARI LAKSHMIKANTHAN | immunology | Women Researcher Award 

Research scholar, University of Madras, India.

Mrs. Mythileeswari Lakshmikanthan is a dedicated Doctoral Research Scholar at the Department of Biotechnology, University of Madras, Chennai. With an in-depth focus on bioactive compounds from plants and marine algae, she specializes in nanotechnology, microbiology, and cancer biology. Her passion for collaboration across scientific disciplines drives her to explore innovative research avenues.

Profile

Scopus

Google Scholar

ORCiD

Education

Mrs. Mythileeswari’s academic journey is anchored at the University of Madras, where she is currently pursuing a Ph.D. in Biotechnology (2023). She holds an M.Phil. in Botany (2008), an M.Sc. in Botany (2007), a B.Ed. in Biological Science (2004), and a B.Sc. in Botany (2003). Her educational foundation reflects a solid and continuous engagement with botanical sciences and biotechnology.

Experience

Over her academic career, Mrs. Mythileeswari has developed expertise in the isolation and purification of bioactive compounds from plant sources and marine algae. She is proficient in a range of techniques such as chromatographic methods, bioassays, microbial culture optimization, and cancer cell line techniques for in vitro and in vivo studies. Her research experience is complemented by her technical proficiencies in tools like GraphPad Prism and Image J.

Research Interests

Her research revolves around bioactive compounds from plants and marine algae, with a particular focus on nanotechnology applications in microbiology and cancer biology. Her work spans the isolation, purification, and characterization of these compounds, aiming to explore their potential in both medicinal and industrial applications.

Awards

Mrs. Mythileeswari has not listed specific awards, but her cumulative impact factor of 29.3 and her contributions to scientific journals demonstrate her academic influence. Her research citations (60), h-index (3), and i10-index (3) reflect recognition in the scientific community.

Publications

Mrs. Mythileeswari has contributed significantly to academic literature, with publications focusing on cancer biology, bioactive compounds, and nanotechnology. Below are some of her key publications:

  1. Sakthivel Muthu, Mythileeswari Lakshmikanthan, et al. (2024). “Encapsulation of Phloroglucinol from Rosenvingea intricata Macroalgae with Zinc Oxide Nanoparticles against A549 Lung Cancer Cells” Pharmaceutics 16(10), 1300. Link (I.F: 4.9).
    • Cited by: None yet.
  2. Mythileeswari Lakshmikanthan et al. (2024). “A Comprehensive Review on Anthocyanin-rich Foods: Insights into Extraction, Medicinal Potential, and Sustainable Applications.” Journal of Agriculture and Food Research 17, 101245. Link (I.F: 4.8).
    • Cited by: None yet.
  3. Sakthivel Muthu, Mythileeswari Lakshmikanthan et al. (2024). “Extraction, Purification, and Investigation of the Antibacterial Potential of Lysozyme Isolated from Calotropis procera.” European Food Research and Technology 250, 1401-1416. Link (I.F: 3.0).
    • Cited by: None yet.
  4. Sakthivel Muthu, Mythileeswari Lakshmikanthan et al. (2019). “A Rapid Synthesis and Antibacterial Property of Selenium Nanoparticles Using Egg White Lysozyme as a Stabilizing Agent.” SN Applied Sciences. Link (I.F: 2.8).
    • Cited by: None yet.
  5. Sakthivel Muthu, Mythileeswari Lakshmikanthan et al. (2017). “Antibacterial Cysteine Protease from Cissus quadrangularis L.” International Journal of Biological Macromolecules 103, 878-888. Link (I.F: 7.7).
    • Cited by: None yet.
  6. Sakthivel Muthu, Mythileeswari Lakshmikanthan et al. (2017). “Antibacterial Serine Protease from Wrightia tinctoria: Purification and Characterization.” Plant Physiology and Biochemistry 112, 161-172. Link (I.F: 6.1).
    • Cited by: None yet.

Conclusion

Mrs. Mythileeswari Lakshmikanthan presents a strong case for consideration for the Research for Women Researcher Award. Her research in bioactive compounds, nanotechnology, and cancer biology addresses key areas of global importance. Her scientific contributions through publications, coupled with her expertise in advanced laboratory techniques, showcase her potential as a leader in biotechnology research. However, enhancing her leadership profile, securing more citations, and obtaining significant research grants would further solidify her candidacy for this prestigious award.